June 20, 2018
FDA letter updates risks of Type III endoleaks with aortic endovascular graft systems
Editor's Note
In a June 19 letter to healthcare providers, the Food & Drug Administration (FDA) says it continues to evaluate information from several sources, including manufacturers, on the risks associated with Type III endoleaks with various endovascular graft systems used for treatment of abdominal aortic aneurysms (AAAs) and aorto-iliac aneurysms.
Based on new information, the FDA says the Endologix AFX with Strata device is at greater risk for Type III endoleaks than other endovascular AAA graft systems.
Free Daily News
- Hospital’s anesthesia reforms slash carbon footprint, expenses
- Study: Shifting imaging to outpatient centers could save billions
- Report: Health system margins shrink as hospital revenue grows
- Study: Cataract surgery increases diabetic retinopathy progression
- FDA announces Class 1 endovascular system, anesthesia system recalls
- Cost-shifting concerns rise as GOP eyes Medicaid cuts
- Study: Prolonged general anesthesia linked to long-term cognitive decline
- Real-time cancer detection improves brain surgery precision
- Research highlights anesthesia provider knowledge gap on drug, hormonal contraceptive interactions
- Healthcare CFOs prioritize cost control, data-driven decisions
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement